JP2012244993A5 - - Google Patents

Download PDF

Info

Publication number
JP2012244993A5
JP2012244993A5 JP2012119327A JP2012119327A JP2012244993A5 JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5 JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012119327 A JP2012119327 A JP 2012119327A JP 2012244993 A5 JP2012244993 A5 JP 2012244993A5
Authority
JP
Japan
Prior art keywords
composition
daclizumab
dac hyp
administered
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012119327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012244993A (ja
JP6055615B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012244993A publication Critical patent/JP2012244993A/ja
Publication of JP2012244993A5 publication Critical patent/JP2012244993A5/ja
Application granted granted Critical
Publication of JP6055615B2 publication Critical patent/JP6055615B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012119327A 2011-05-27 2012-05-25 Ｄａｃｈｙｐ組成物および方法 Expired - Fee Related JP6055615B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016161679A Division JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法

Publications (3)

Publication Number Publication Date
JP2012244993A JP2012244993A (ja) 2012-12-13
JP2012244993A5 true JP2012244993A5 (enExample) 2015-04-09
JP6055615B2 JP6055615B2 (ja) 2016-12-27

Family

ID=46177353

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012119327A Expired - Fee Related JP6055615B2 (ja) 2011-05-27 2012-05-25 Ｄａｃｈｙｐ組成物および方法
JP2016161679A Pending JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法
JP2018073025A Pending JP2018134091A (ja) 2011-05-27 2018-04-05 Ｄａｃ ｈｙｐ組成物および方法
JP2020034673A Withdrawn JP2020078348A (ja) 2011-05-27 2020-03-02 Ｄａｃ ｈｙｐ組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016161679A Pending JP2016210796A (ja) 2011-05-27 2016-08-22 Ｄａｃ ｈｙｐ組成物および方法
JP2018073025A Pending JP2018134091A (ja) 2011-05-27 2018-04-05 Ｄａｃ ｈｙｐ組成物および方法
JP2020034673A Withdrawn JP2020078348A (ja) 2011-05-27 2020-03-02 Ｄａｃ ｈｙｐ組成物および方法

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN102796705A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2661764C2 (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2777978A1 (en) 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods
WO2013022972A1 (en) * 2011-08-08 2013-02-14 Abbott Biotherapeutics Corporation Methods of treating progressive forms of multiple sclerosis
US20140295497A1 (en) * 2011-11-30 2014-10-02 Taymar E. Hartman Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2015034566A1 (en) * 2013-09-04 2015-03-12 Emd Millipore Corporation Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
WO2016154290A1 (en) * 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
MX383558B (es) * 2015-08-12 2025-03-14 Pfizer Cisteinas de anticuerpo con capuchon y sin capuchon y su uso en conjugacion de anticuerpo-farmaco
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
JP7479151B2 (ja) * 2017-01-30 2024-05-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーにおけるバイオバーデンを低減するための組成物および方法
JP7786876B2 (ja) * 2017-12-21 2025-12-16 ジェンザイム・コーポレーション プロテインａクロマトグラフィー中の不純物の除去を促進する方法
EP3956046A1 (en) * 2019-04-17 2022-02-23 Bristol-Myers Squibb Company Methods for regenerating chromatography resins
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
US20220259261A1 (en) * 2019-08-01 2022-08-18 Regeneron Pharmaceuticals, Inc. Method for viral inactivation
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
KR20240004718A (ko) * 2021-05-03 2024-01-11 베링거 인겔하임 인터내셔날 게엠베하 스페솔리맙의 제조방법
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
EP2035034A4 (en) 2006-06-09 2009-11-18 Univ Maryland GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY
JP2010510963A (ja) * 2006-06-14 2010-04-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー セラミックヒドロキシアパタイトを使用する抗体の精製方法
US20090209656A1 (en) * 2006-07-06 2009-08-20 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
EP2271669A1 (en) * 2008-03-11 2011-01-12 Genentech, Inc. Antibodies with enhanced adcc function
RU2011111391A (ru) * 2008-08-28 2012-10-10 Эбботт Байотерапьютикс Корп. (Us) Способ лечения пациентов, страдающих рассеянным склерозом, антителами анти-il2r
WO2010138502A2 (en) * 2009-05-26 2010-12-02 Momenta Pharmaceuticals, Inc. Production of glycoproteins
US20120277165A1 (en) 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
ES2817802T3 (es) * 2009-08-07 2021-04-08 Emd Millipore Corp Métodos para purificar una proteína objetivo de una o más impurezas en una muestra
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
PT2542590T (pt) 2010-03-05 2017-08-31 Univ Johns Hopkins Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
CA2777978A1 (en) * 2011-05-27 2012-11-27 Abbott Biotherapeutics Corp. Dac hyp compositions and methods

Similar Documents

Publication Publication Date Title
RU2018119112A (ru) Композиции и способы на основе dac hyp
EP2964674B1 (en) Anti-tnf-anti-il-17 bispecific antibodies
TW516962B (en) A human TNFR1-IgG1 preparation
EP3063174B1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
US20080167450A1 (en) Methods of purifying proteins
KR20120100914A (ko) 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료
AU2017206006B2 (en) Modulation of afucosylated species in a monoclonal antibody composition
EP2844290A1 (en) Novel antibodies
JP6514789B2 (ja) 新規組換え抗ＴＮＦ−αキメラモノクローナル抗体の製造方法及び用途
US20190048070A1 (en) Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
EP3101035A1 (en) Bifunctional fusion protein, preparation method therefor, and use thereof
CN107208081B (zh) 用于从包含污染宿主细胞蛋白质的材料纯化重组人α-半乳糖苷酶A的方法
WO2017038986A1 (ja) 組換えタンパク質の製造方法
TWI891671B (zh) 血清白蛋白與生長激素之融合蛋白質之製造方法
HK40091815A (zh) 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
HK40091814A (zh) 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
HK1241916A1 (en) Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins